Goldridge Terminal 로고 Goldridge Terminal
인기
로그인

관심목록에 추가
Pro 차트

AgomAb Therapeutics NV

NasdaqGS: AGMB · 실시간 가격 · USD
14.11
-0.74 (-4.98%)
종가 기준: Aug 12, 2026, 3:59 PM
14.11
+0.00%
애프터마켓: 7:34 PM

AgomAb Therapeutics NV (AGMB) Stock Price, Analysis & Data

-4.98%
매수호가11.05
시가총액694.89M
매출 (ttm)n/a
순이익 (ttm)-81.6M
베타n/a
EPS (ttm)-1.56
P/E (ttm)n/a
선행 P/E-6.84
P/B (ttm)5.39
P/S (ttm)n/a
Earnings Daten/a
매도호가17.98
거래량151,048
평균 거래량 (20일)93,614
시가14.85
전일 종가14.85
일중 범위13.80 - 15.58
52주 범위8.75 - 17.82
애널리스트Strong Buy
목표주가34 (140.96%)
배당n/a
배당락일n/a

AGMB 소개

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule i...

[더 보기]
산업 Biotechnology
섹터 Healthcare
IPO 일자 Feb 6, 2026
직원 수 62
상장 거래소 NasdaqGS
티커 AGMB
웹사이트 https://www.agomab.com
전체 기업 정보

재무 실적

2025년 AgomAb Therapeutics NV의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -62.55M로, 35.19% 증가했습니다.

재무제표

애널리스트 전망

애널리스트 5명의 투자의견을 종합하면 AGMB 주식의 평균 등급은 "Strong Buy"입니다. 12개월 목표주가는 34로, 최근 주가 대비 140.96% 상승 여력입니다.

주가 전망
news image

1개월 전 · Insider Monkey

Is AgomAB Therapeutics NV (AGMB) Stock a Biotech Opportunity With Targeted Tissue Therapy Potential?

We recently compiled a list of the 8 Best Up and Coming Pharmaceutical Stocks to Buy Now. AgomAB Therapeutics NV (NASDAQ:AGMB) is one of the best up and coming stocks on our list. TheFly reported on J...

news image

1개월 전 · MT Newswires

Agomab Therapeutics Shares NOV-ERA Phase 2b Study Design With Ontunisertib in Fibrostenosing Crohn's Disease

Agomab Therapeutics (AGMB) said late Tuesday it has designed its upcoming phase 2b NOV-ERA study wit

news image

4개월 전 · Insider Monkey

AgomAb Therapeutics (AGMB) Wins U.S. Patent for AGMB-447

AgomAb Therapeutics NV (NASDAQ:AGMB) is one of the 7 Best Strong Buy European Stocks to Invest In. On March 26, 2026, AgomAb Therapeutics NV (NASDAQ:AGMB) announced that the U.S. Patent and Trademark ...

news image

5개월 전 · MT Newswires

European Equities Traded in the US as American Depositary Receipts Higher Wednesday

European equities traded in the US as American depositary receipts were rising on Wednesday morning,

news image

6개월 전 · TipRanks

Agomab indicated to open at $15.50, IPO priced at $16

Agomab (AGMB) priced 12.5M shares at $16.00, inside the $15.00-$17.00 target range. JPMorgan, Morgan Stanley, Leerink and Kempen are acting as joint book running managers for the offering. Agomab is a...